Blood products sit under a special regulatory regime in China, separate from ordinary medicines. They cannot be sold online, they cannot be contract-manufactured, and their import and export are governed by rules that have been in force, with only narrow exceptions, for decades. For a buyer, the practical question is simple: which Chinese plasma products can legally reach my market, and which cannot reach China at all?
The two rules that govern everything
| Rule | What it says | Practical effect |
|---|---|---|
| Export of source plasma | Prohibited under the Blood Products Administration Regulation (Article 19) | Only finished, registered products leave China; raw plasma never does |
| Import of blood products | Restricted to human albumin and recombinant factor VIII since 1985 / 2007 | Plasma-derived factor VIII, IVIG and immunoglobulins cannot be imported into China |
These two rules are asymmetric. China is a major exporter of finished plasma products, but an almost closed importer of them. A buyer sourcing out of China is therefore working with the export side of the framework, not the import side — though the import rules still matter, because they explain why some product forms exist only as domestic registrations and never appear in an export catalogue.
What China will not import
The import restriction dates to 1985, when China barred blood-product imports to prevent the introduction of HIV through imported blood products — with a single exception for human albumin. That restriction has held. The one material change came in 2007, when recombinant factor VIII was permitted to relieve a shortage for haemophilia patients.
| Product | Import status into China |
|---|---|
| Human serum albumin | Permitted (sole original exception since 1985) |
| Recombinant coagulation factor VIII | Permitted since November 2007 |
| Plasma-derived coagulation factor VIII | Prohibited |
| IVIG (intravenous immunoglobulin) | Prohibited |
| Other immunoglobulins | Prohibited |
Two further restrictions compound the picture. Since 2002, albumin sourced from bovine spongiform encephalopathy (BSE) affected regions is barred. And under the 2017 biologics lot-release measures, any product that has not passed state batch release may not be marketed or imported — so batch release is a precondition of trade in both directions.
What China will not export
On the export side, the binding rule is the ban on source plasma. The Blood Products Administration Regulation states plainly that the state prohibits the export of source plasma, and manufacturers may not supply source plasma to any other party. What this means for a buyer is that a legitimate Chinese export is always a finished, registered product — never a bulk or intermediate material.
If someone offers to ship you Chinese source plasma, or bulk plasma intermediates, the offer is already outside the law. Legitimate Chinese plasma export means finished, batch-released, registered product.
Why this shapes the product catalogue
The import restrictions explain a pattern that confuses first-time buyers: China produces plasma-derived factor VIII, IVIG and immunoglobulins for its domestic market and for export to other countries — but does not import those same products back. So a product like plasma-derived factor VIII is entirely legitimate as a Chinese export, while being simultaneously closed as a Chinese import.
That asymmetry is the single most useful fact to internalise. It means:
- A Chinese plasma-derived product is not "unapproved" just because China does not import it — export and import run under different rules.
- The question that matters for your market is your country's import rules, not China's.
- Recombinant factor VIII is the one factor product that moves in both directions, which is why it is compared against the plasma-derived form separately.
How these rules fit the rest of the file
- Batch release — the state lot-release gate that both trade directions must pass.
- Certificate of Pharmaceutical Product — the registration evidence the importing regulator reads.
- Verifying the approval number — confirming a product is a real registered product before it ships.
Frequently asked questions
Which blood products can be imported into China?
In practice only two categories: human serum albumin and recombinant coagulation factor VIII. Since 1985 China has barred the import of other blood products, including plasma-derived factor VIII, IVIG and immunoglobulins. Recombinant factor VIII has been allowed since November 2007.
Can source plasma be exported from China?
No. The Blood Products Administration Regulation explicitly prohibits the export of source plasma, and blood-product manufacturers are not allowed to supply source plasma to any other party. Only finished, registered products may be exported.
Can plasma-derived factor VIII be imported into China?
No. Plasma-derived factor VIII is barred from import. Only recombinant factor VIII has been permitted since 2007. This is a key reason buyers weigh the two forms separately — the regulatory path is not the same.
What does batch release have to do with import and export?
Under the 2017 biologics lot-release measures, a product that has not passed state batch release may not be marketed or imported. Batch release authorises domestic sale; export authorisation is a separate certificate for the product and destination.
Are these rules the same as the importing country's rules?
No. China's rules govern what leaves and enters China. The importing country has its own registration and import rules, which a buyer must satisfy separately. A product lawful to export from China may still need local registration to enter another market.
Where to go next
- How to import blood products from China — the destination-by-destination path, once you know what China will ship.
- Plasma-derived vs recombinant factor VIII — why the import asymmetry makes the two forms different propositions.
- Product index — the registered products we export, with their approval references.